NasdaqCM - Nasdaq Real Time Price USD

Precipio, Inc. (PRPO)

6.21 +0.03 (+0.55%)
As of 9:32 AM EDT. Market Open.
Loading Chart for PRPO
DELL
  • Previous Close 6.18
  • Open 6.21
  • Bid 4.90 x 100
  • Ask 7.19 x 100
  • Day's Range 6.21 - 6.21
  • 52 Week Range 4.75 - 14.80
  • Volume 760
  • Avg. Volume 5,212
  • Market Cap (intraday) 8.888M
  • Beta (5Y Monthly) 1.25
  • PE Ratio (TTM) --
  • EPS (TTM) -4.51
  • Earnings Date May 15, 2024 - May 20, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 19.00

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.

www.precipiodx.com

51

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PRPO

Performance Overview: PRPO

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PRPO
4.40%
S&P 500
6.86%

1-Year Return

PRPO
49.15%
S&P 500
25.19%

3-Year Return

PRPO
83.73%
S&P 500
21.94%

5-Year Return

PRPO
95.58%
S&P 500
74.19%

Compare To: PRPO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PRPO

Valuation Measures

Annual
As of 4/25/2024
  • Market Cap

    8.83M

  • Enterprise Value

    8.45M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.53

  • Price/Book (mrq)

    0.61

  • Enterprise Value/Revenue

    0.56

  • Enterprise Value/EBITDA

    -1.96

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -38.51%

  • Return on Assets (ttm)

    -24.05%

  • Return on Equity (ttm)

    -38.01%

  • Revenue (ttm)

    15.2M

  • Net Income Avi to Common (ttm)

    -5.85M

  • Diluted EPS (ttm)

    -4.51

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.5M

  • Total Debt/Equity (mrq)

    7.73%

  • Levered Free Cash Flow (ttm)

    -2.75M

Research Analysis: PRPO

Analyst Price Targets

19.00
19.00 Average
6.21 Current
19.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: PRPO

Fair Value

6.21 Current
 

Dividend Score

0 Low
PRPO
Sector Avg.
100 High
 

Hiring Score

0 Low
PRPO
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
PRPO
Sector Avg.
100 High
 

People Also Watch